Loading data for KRYS — first visit, this takes a few seconds.
Krystal Biotech, Inc.
336.68 -3.35 (-0.99%)
336.68 +0.00%
- Market Cap
- $9.97B
- Volume
- 226K
- Dividend yield
- n/a
- Next earnings date
- Nov 2, 2026
Krystal Biotech, Inc. (KRYS) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $119.2M | n/a | +24.14% |
| EPS | $1.79 | -$0.12 | +38.76% |
Metrics
- Bid
- 352.61
- Market Cap
- 9.97B
- Revenue (ttm)
- 440M
- Net Income (ttm)
- 241M
- 0.54
- 7.99
- 42.14
- 35.83
- P/B (ttm)
- 7.33
- P/S (ttm)
- 22.62
- Earnings Date
- Nov 2, 2026
- Ask
- 345.36
- Volume
- 225,770
- Avg. Volume (20D)
- 406,125
- Open
- 339.01
- Previous Close
- 340.03
- Day's Range
- 331.79 - 340.09
- 52-Week Range
- 151.88 - 382.54
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Krystal Biotech, Inc.
View profile →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 295
Stock Exchange NasdaqGS
Ticker Symbol KRYS
Website https://www.krystalbio.com